Image credit: Gorodenkoff via Shutterstock. The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 is a strategic platform for discussion and collaboration among decision makers, researchers
The growing global demand for cell and gene therapies (CGTs) is resulting in a manufacturing paradigm shift, reflecting the need to overcome a range of
With the approval date for Bristol Myers Squibb’s (BMS) schizophrenia drug KarXT (xanomeline-trospium) looming, prodrugs – medications that start as inactive or less active, and
A patient with hereditary angioedema (HAE). Image credit: Velimir Zeland / Shutterstock. Astria Therapeutics has selected Ypsomed’s Ypsomate autoinjector as its partner for the administration
The FDA’s pilot programme is set to accelerate the development of novel drug and biological products for rare diseases. Credit: Tada Images via Shutterstock. US-based
Ralph Carmona was enrolled into a clinical trial of Leqembi in 2015. Image credit: meeboonstudio / Shutterstock. During a session at the 2024 Alzheimer’s Association
In 2023, EcoVadis awarded Boehringer Ingelheim with a silver rating for its For Generations framework. Image credit: Shutterstock / petrmalinak Frameworks for environmental, social, and
Some 2seventy bio team members that have been working on the haemophilia A program will now be joining Novo Nordisk. Image Credit: Andrey_Popov/Shutterstock. US-based 2seventy
Image credit: Shutterstock/Peakstock Analytics firm Target RWE has published its findings that 99% of participants in TARGET-NASH, a research registry of patients with nonalcoholic fatty
Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany. Credit: Lightspring / Shutterstock. Cancer-focused biotech